266 related articles for article (PubMed ID: 37374378)
1. New Options for Systemic Therapies in Intrahepatic Cholangiocarcinoma (iCCA).
Becht R; Wasilewicz MP
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374378
[TBL] [Abstract][Full Text] [Related]
2. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma.
Bath NM; Pawlik TM
Chin Clin Oncol; 2023 Feb; 12(1):5. PubMed ID: 36922354
[TBL] [Abstract][Full Text] [Related]
3. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
4. Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach.
Merath K; Tiwari A; Parikh AA; Pawlik TM
Future Oncol; 2023 Dec; 19(39):2607-2621. PubMed ID: 38108100
[TBL] [Abstract][Full Text] [Related]
5. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Aitcheson G; Mahipal A; John BV
Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
[No Abstract] [Full Text] [Related]
6. Systemic treatment of advanced or recurrent biliary tract cancer.
Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
[TBL] [Abstract][Full Text] [Related]
7. Systemic therapies for intrahepatic cholangiocarcinoma.
Kelley RK; Bridgewater J; Gores GJ; Zhu AX
J Hepatol; 2020 Feb; 72(2):353-363. PubMed ID: 31954497
[TBL] [Abstract][Full Text] [Related]
8. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
[TBL] [Abstract][Full Text] [Related]
9. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
[TBL] [Abstract][Full Text] [Related]
10. Emerging molecular therapeutic targets for cholangiocarcinoma.
Ilyas SI; Gores GJ
J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
[TBL] [Abstract][Full Text] [Related]
11. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians.
Moris D; Palta M; Kim C; Allen PJ; Morse MA; Lidsky ME
CA Cancer J Clin; 2023 Mar; 73(2):198-222. PubMed ID: 36260350
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of ivosidenib for the treatment of
Tella SH; Mahipal A
Expert Opin Pharmacother; 2022 Dec; 23(17):1879-1885. PubMed ID: 36257911
[TBL] [Abstract][Full Text] [Related]
13. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.
Saborowski A; Vogel A; Segatto O
Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108
[TBL] [Abstract][Full Text] [Related]
14. FGFR2 Inhibition in Cholangiocarcinoma.
Vogel A; Segatto O; Stenzinger A; Saborowski A
Annu Rev Med; 2023 Jan; 74():293-306. PubMed ID: 36170665
[TBL] [Abstract][Full Text] [Related]
15. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.
Brown ZJ; Ruff SM; Pawlik TM
Expert Rev Anticancer Ther; 2023 Mar; 23(3):257-264. PubMed ID: 36744395
[TBL] [Abstract][Full Text] [Related]
16. How I treat biliary tract cancer.
Lamarca A; Edeline J; Goyal L
ESMO Open; 2022 Feb; 7(1):100378. PubMed ID: 35032765
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma.
Tsujie M; Iwai T; Kubo S; Ura T; Hatano E; Sakai D; Takeda Y; Kaibori M; Kobayashi T; Katanuma A; Katayose Y; Fukase K
Jpn J Clin Oncol; 2021 May; 51(6):911-917. PubMed ID: 33822966
[TBL] [Abstract][Full Text] [Related]
18. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
Komuta M
Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
[TBL] [Abstract][Full Text] [Related]
19. Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma.
Zhang Z; Wang G; Du L; Zhao J; Pan L; Zhang G; Wang F; Liu R
Front Immunol; 2023; 14():1124482. PubMed ID: 37292215
[TBL] [Abstract][Full Text] [Related]
20. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications.
Kankeu Fonkoua LA; Serrano Uson Junior PL; Mody K; Mahipal A; Borad MJ; Roberts LR
Expert Opin Ther Targets; 2022 Jan; 26(1):79-92. PubMed ID: 35034558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
